ICON Public (NASDAQ:ICLR) Sees Strong Trading Volume – Here’s Why

by · The Markets Daily

ICON Public Limited (NASDAQ:ICLR – Get Free Report) saw an uptick in trading volume on Friday . 1,249,277 shares were traded during trading, an increase of 103% from the previous session’s volume of 614,583 shares.The stock last traded at $227.58 and had previously closed at $221.73.

Wall Street Analyst Weigh In

Several research firms recently weighed in on ICLR. Robert W. Baird cut shares of ICON Public from an “outperform” rating to a “neutral” rating and set a $340.00 price target on the stock. in a report on Thursday. Truist Financial cut their price target on shares of ICON Public from $383.00 to $363.00 and set a “buy” rating on the stock in a report on Monday, October 14th. The Goldman Sachs Group cut their price target on shares of ICON Public from $370.00 to $280.00 and set a “buy” rating on the stock in a report on Friday. Leerink Partners cut their price target on shares of ICON Public from $376.00 to $270.00 and set an “outperform” rating on the stock in a report on Friday. Finally, Barclays cut their price target on shares of ICON Public from $330.00 to $275.00 and set an “overweight” rating on the stock in a report on Friday. Four research analysts have rated the stock with a hold rating, ten have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $310.45.

Read Our Latest Stock Report on ICLR

ICON Public Stock Down 0.6 %

The company has a market capitalization of $18.19 billion, a PE ratio of 25.70, a PEG ratio of 1.35 and a beta of 1.22. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.31 and a current ratio of 1.31. The stock’s 50 day moving average is $297.75 and its 200 day moving average is $310.20.

ICON Public (NASDAQ:ICLR – Get Free Report) last announced its quarterly earnings results on Wednesday, October 23rd. The medical research company reported $3.35 EPS for the quarter, missing analysts’ consensus estimates of $3.72 by ($0.37). The business had revenue of $2.03 billion for the quarter, compared to analysts’ expectations of $2.13 billion. ICON Public had a net margin of 8.57% and a return on equity of 12.06%. The business’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same quarter in the previous year, the company posted $3.10 earnings per share. On average, sell-side analysts anticipate that ICON Public Limited will post 14.53 EPS for the current fiscal year.

Institutional Trading of ICON Public

Institutional investors have recently modified their holdings of the business. Whittier Trust Co. increased its holdings in ICON Public by 21.9% during the 1st quarter. Whittier Trust Co. now owns 3,295 shares of the medical research company’s stock worth $1,107,000 after acquiring an additional 593 shares during the period. Whittier Trust Co. of Nevada Inc. increased its holdings in ICON Public by 410.8% during the 1st quarter. Whittier Trust Co. of Nevada Inc. now owns 189 shares of the medical research company’s stock worth $63,000 after acquiring an additional 152 shares during the period. First National Bank of Hutchinson increased its holdings in ICON Public by 5.7% during the 1st quarter. First National Bank of Hutchinson now owns 1,135 shares of the medical research company’s stock worth $381,000 after acquiring an additional 61 shares during the period. Motco increased its holdings in ICON Public by 1.5% during the 1st quarter. Motco now owns 3,882 shares of the medical research company’s stock worth $1,304,000 after acquiring an additional 59 shares during the period. Finally, SkyView Investment Advisors LLC bought a new stake in ICON Public during the 1st quarter worth approximately $1,021,000. 95.61% of the stock is currently owned by hedge funds and other institutional investors.

About ICON Public

(Get Free Report)

ICON Public Limited Company, a clinical research organization, provides outsourced development and commercialization services in Ireland, rest of Europe, the United States, and internationally. The company specializes in the strategic development, management, and analysis of programs that support various stages of the clinical development process from compound selection to Phase I-IV clinical studies.

Recommended Stories